Kalohexis
Manufacturing · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1935 Techny Rd Ste 14, Northbrook, Illin...Website
www.kalohexis.comRevenue
$6.4 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Kalohexis
Kalohexis is a clinical-stage biotechnology company focused on developing next-generation peptide therapeutics by targeting the melanocortin system. Spun out from Endevica Bio, the firm aims to address obesity and cancer cachexia.Explore more
Kalohexis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kalohexis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Kalohexis, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Kalohexis
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Kalohexis had a recent Job posting/layoffs
Check if Kalohexis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Kalohexis launches new products
Funding: Get notified immidiatlly once Kalohexis has new funding data
Check out if Kalohexis is spiking on competitors!
Earning: See what the market has to say on Kalohexis recently announced quarterly report
Recommended Actions
Find VP level buyers at Kalohexis
Find 3 more new buyers
Kalohexis News & Media
Kalohexis Appoints Life Sciences Leader, Jeffrey Sherman, MD, to Board of Directors
Dr. Sherman, former CMO of Horizon Therapeutics, brings over 35 years of R&D and regulatory expertise NORTHBROOK, Ill., Aug. 11, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care...Kalohexis Presents Data Demonstrating Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates at ICO 2026
710GO, Kalohexis' novel oral dual MC3R/MC4R agonist, is currently being evaluated in a Phase 1 clinical trial as a potentially healthier and more durable treatment for general obesity NORTHBROOK, Ill., July 15, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company...Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
NORTHBROOK, Ill., July 7, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the confidential submission of a draft...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kalohexis
Sign Up For FreeTo access detailed company insights
Kalohexis is a clinical-stage biotechnology company focused on developing next-generation peptide therapeutics by targeting the melanocortin system. Spun out from Endevica Bio, the firm aims to address obesity and cancer cachexia.... Read More
